Background: Myocardial fibrosis is the major factor that regulates left ventricular (LV) diastolic function. Pioglitazone, an anti-diabetic drug, is reported to improve the LV diastolic function in diabetic patients, but its influence on myocardial fibrosis has not been clarified. We evaluated the effect of pioglitazone on LV diastolic function and myocardial fibrosis in type 2 diabetic (T2DM) patients. Methods and results: Fifteen T2DM patients were enrolled in the ON group, and the parameters were examined before and after pioglitazone administration (15-30 mg/day) for 6 months. Twenty-four T2DM patients were assigned to the OFF group, and the parameters were examined before and 6 months after cessation of pioglitazone. We measured echocardiographic parameters such as early diastolic mitral annular velocity (E ) and plasma concentration of aminoterminal propeptide of procollagen type III (PIIIP), a marker of myocardial fibrosis. In the ON group, pioglitazone significantly increased E (6.04 ± 1.70 cm/s vs. 6.51 ± 1.64 cm/s, p < 0.01) and decreased PIIIP (0.553 ± 0.056 U/ml vs. 0.517 ± 0.072 U/ml, p < 0.05). There was a significant negative correlation between the change in PIIIP and the change in E (r = −0.424, p = 0.046). On the other hand, E was significantly decreased (5.69 ± 1.34 cm/s vs. 4.97 ± 1.20 cm/s, p < 0.01) in the OFF group. PIIIP was not significantly changed in the OFF group, but there was a significant negative correlation between the change in PIIIP and the change in E (r = −0.374, p = 0.035). * Corresponding author. Tel.: +81 18 829 5000; fax: +81 18 829 5255. E-mail address: gterui@archosp-1998.com (G. Terui). Effect of pioglitazone on left ventricular diastolic function and fibrosis 53 Conclusion: Six months of pioglitazone administration suppressed the synthesis of type III collagen, and this was associated with improved LV diastolic function in T2DM patients. Cessation of pioglitazone weakened the suppression of the synthesis of type III collagen, which in turn seemed to be associated with worse LV diastolic function.
Introduction
The thiazolidine derivative pioglitazone, a peroxisome proliferator-activated receptor (PPAR)-␥ agonist, is currently used as an anti-diabetic drug. It is reported to have a variety of actions in addition to a hypoglycemic action and an ameliorating effect on insulin resistance. Improvement of abnormal lipid metabolism, an anti-inflammatory effect, an anti-atherogenic action, and an inhibitory effect on oxidative stress have been reported. With respect to the heart, it was reported to inhibit myocardial cell hypertrophy in rats [1] , inhibit myocardial fibrosis in a rat model of diabetes [2] , inhibit progression of human coronary artery atherosclerosis [3] , and inhibit recurrence of cardiovascular events [4] . We previously reported that pioglitazone improved left ventricular diastolic function in type 2 diabetic patients [5] . Myocardial fibrosis is the major factor that regulates left ventricular diastolic function. Moreover, it has been reported that a relationship was observed between aminoterminal propeptide of procollagen type III (PIIIP), a marker of myocardial fibrosis, and heart failure in humans [6] [7] [8] [9] . The purpose of the present study is to investigate how left ventricular diastolic function and PIIIP change as a result of initiation of oral administration of pioglitazone and discontinuation of oral administration in type 2 diabetic patients.
Methods

Subjects and study protocol
We studied 15 patients with type 2 diabetes in the ON group (8 men and 7 women; mean age, 67.8 years) and 24 patients with type 2 diabetes in the OFF group (12 men and 12 women; mean age, 67.2 years). Patients were excluded if they had heart failure, left ventricular systolic failure, moderate-to-severe valvular disease, atrial fibrillation, liver dysfunction, collagen disease, renal failure, pulmonary fibrosis, or osteoporosis.
During this study, the doses of neither antihypertensive drugs nor anti-diabetic drugs were changed. Informed consent was obtained from all patients before participation in the study, and the protocol was approved by the Human Investigations Committee of our institution. Parameters were examined before and after pioglitazone administration (15-30 mg/day) for 6 months in the ON group, and they were examined before and 6 months after cessation of pioglitazone in the OFF group.
Echocardiography
M-mode echocardiography and two-dimensional imaging were performed using a cardiac ultrasound unit (SONOS 5500; Hewlett Packard, Andover, MA, USA) in a blinded fashion before and after treatment. Each patient was examined in the left lateral decubitus position. Measurements included left ventricular ejection fraction (LVEF) calculated using Teichholtz's formula, left ventricular Tei index (LVTEI) [10] , and left ventricular mass index (LVMI) [11] . Assessment of early diastolic mitral annular velocity (E ) was performed by pulsed wave tissue Doppler imaging of the septal wall in apical 4-chamber view. Doppler echocardiogram was recorded at a sweep of 50 mm/s and the mean value of three cardiac cycles was obtained. After measurement of cardiac parameters, blood pressure at the brachial artery and body weight were measured.
Plasma sample measurements
Blood samples were collected from an antecubital vein in the supine position before and after 6 months of treatment. Plasma PIIIP level was measured with a specific immunoradiometric assay using a commercial kit (CIS Bio International, Nagoya, Japan).
Statistical analysis
Data are expressed as mean ± standard deviation (S.D.). Paired t-test was used for comparison of intragroup data. Linear regression analysis was used 
Results
On enrollment in the study, 6 patients in the ON group and 13 patients in the OFF group were treated for hypertension. Of those, 3 and 7 patients, respectively, were taking angiotensin-converting enzyme inhibitors or angiotensin II type I receptor blockers. Fourteen and 21 patients, respectively, were taking anti-diabetic drugs other than pioglitazone. The breakdown of anti-diabetic drugs that were taken was as follows: a sulfonylurea agent in 4 and 9 patients, a biguanide agent in 10 and 15 patients, an alpha-glucosidase inhibitor in 4 and 4 patients, and insulin in 3 and 5 patients, respectively. The duration of diabetes was 9.5 ± 9.1 and 13.2 ± 6.6 years, respectively (Table 1 ).
In the ON group, no significant change in heart rate or body weight was observed, and mean blood pressure (mBP) decreased significantly (93.2 ± 6.6 mmHg vs. 89.1 ± 6.4 mmHg (mean ± S.D.), p < 0.05). Hemoglobin A1c (HbA1c) decreased significantly (7.8 ± 1.0% vs. 6.9 ± 0.7%, p < 0.01). Brain natriuretic peptide (BNP) was unchanged (31.7 ± 41.3 pg/ml vs. 29.2 ± 46.6 pg/ml). Creatinine was unchanged (0.59 ± 0.17 mg/dl vs. 0.63 ± 0.18 mg/dl). Urinary albumin excretion (U-Alb) was unchanged (38.9 ± 46.6 mg/gCr vs. 39.7 ± 50.2 mg/gCr). PIIIP decreased significantly (0.553 ± 0.056 U/ml vs. 0.517 ± 0.072 U/ml, p < 0.05). LVEF was unchanged (0.66 ± 0.60 vs. 0.66 ± 0.56), LVMI was unchanged (120.2 ± 23.9 g/m 2 vs. 121.1 ± 21.4 g/m 2 ), and LVTEI decreased significantly (0.446 ± 0.114 vs. 0.382 ± 0.086, p < 0.01). E increased significantly (6.04 ± 1.70 cm/s vs. 6.51 ± 1.64 cm/s, p < 0.01) ( Table 2) . Moreover, a negative correlation was seen between change in PIIIP (%PIIIP) and change in E (%E ) (r = −0.424, p = 0.046) (Fig. 1) . Furthermore, there was no correlation between change in mean blood pressure (%mBP) and change in E (%E ) (Fig. 2) or between change in HbA1c (%HbA1c) and change in E (%E ) (Fig. 3) .
The mean duration of exposure to oral pioglitazone in the OFF group was 16.9 months. No significant change in heart rate, mBP, body weight, BNP, creatinine, U-Alb, HbA1c, PIIIP, LVEF, or LVMI was observed. LVTEI increased significantly (0.371 ± 0.083 vs. 0.439 ± 0.098, p < 0.01). E decreased significantly (5.69 ± 1.34 cm/s vs. 4.97 ± 1.20 cm/s, p < 0.01) (Table 3) . Moreover, a negative correlation was seen between change in PIIIP (%PIIIP) and change in E (%E ) (r = −0.374, p = 0.035) (Fig. 1) . Furthermore, there was no correlation between change in mean blood pressure (%mBP) and change in E (%E ) (Fig. 2) or between change in HbA1c (%HbA1c) and change in E (%E ) (Fig. 3) .
Discussion
In addition to a hypoglycemic action, pioglitazone, an oral anti-diabetic drug, is reported to have an anti-atherogenic action and an antiinflammatory effect [12] , and it is reported to lower oxidative stress and left ventricular collagen content [13] , in animal experimental models. Using cardiomyocyte-and macrophage-specific PPAR␥ knockout mice, PPAR␥ ligand pioglitazone could attenuate angiotensin II-induced cardiac fibrosis by attenuating monocyte inflammatory behavior and by inhibiting myocardial macrophage infiltration [14] . This action of PPAR␥ ligands may be an adjunct therapy to renin-angiotensin-aldosterone system inhibition, but these putative anti-inflammatory cardiac actions of PPAR␥ need to be confirmed in humans. In humans, it is reported to have lowered intima-media complex thickness of the carotid artery [15] and to have exhibited an antiatherogenic action/anti-inflammatory effect [16] . Pioglitazone was expected to improve heart function given its potential vasodilatory effect [17] . A large-scale observational study showed that thiazolidine derivatives and metformin improved the overall mortality rate of elderly patients with a history of diabetes and heart failure as compared with other anti-diabetic drugs and insulin [18] . In addition, it was reported that metformin improved the prognosis of heart failure patients with diabetes as compared with sulfonylurea [19] , and that it inhibited onset of cardiovascular events in diabetic patients with a history of macrovascular disease [4] . In all of the above cases, it can be said that improvement of insulin resistance led to the outcome of an improved prognosis in patients with heart failure. Given these findings, while retention of water in the body was a known adverse drug reaction [20] , direct effects on the heart like those mentioned above were expected. Therefore, we investigated the effect of pioglitazone on left ventricular diastolic function using echocardiography, and we reported that pioglitazone improved left ventricular diastolic function in type 2 diabetic patients [5] . In the present study, we investigated the association between left ventricular diastolic function, as measured by echocardiography, and PIIIP, a marker of myocardial fibrosis, at initiation of oral administration of pioglitazone and after discontinuation of administration, to elucidate the mechanism. Type III collagen is the primary constituent of the myocardial collagen matrix. It is produced by cardiac fibroblasts [21] and is responsible for structural maintenance of elastic organs [22] . PIIIP is considered to be an indicator of type III collagen synthesis. PIIIP levels reflect the degree of myocardial fibrosis in dilated cardiomyopathy patients [6] , chronic heart failure patients [7] , and recent myocardial infarction patients [8] , and it is reported to be associated with cardiac function or vital prognosis. Moreover, it is reported that intramyocardial collagen turnover is associated with the severity of dilated heart failure [9] . Therefore, we measured PIIIP as an indicator of myocardial fibrosis. The plasma PIIIP level in healthy subjects was 0.496 ± 0.074 U/ml (n = 18, age 66.4 ± 13.5 years), which was significantly lower than that in patients in the ON group and OFF group. In the present study, which included diabetic patients with or without hypertension, it could be surmised that myocardial fibrosis had progressed relative to baseline in both groups.
Compared to non-diabetic patients, more diabetic patients suffer from ischemic heart disease and abnormal left ventricular function. Multidetector computed tomography with coronary angiography has been reported to be useful, as a non-invasive clinical modality for ischemic heart disease [23] . Echocardiography is chiefly used for detecting abnormal left ventricular function. E was used to represent left ventricular diastolic function. This is calculated as early diastolic mitral annular velocity using pulsed wave tissue Doppler imaging. It is a non-invasive modality that uses echocardiography. It is said to be less susceptible to the effects of preloading [24] .
In the ON group, since mean baseline E was 6.04 cm/s, which was low, and LVTEI was 0.446, which exceeded the upper limit of normal, we confirmed that the type 2 diabetic patients enrolled in this study suffered from decreased left ventricular diastolic function even though left ventricular systolic function was within the normal range. Initiation of oral administration of pioglitazone resulted in a significant increase in E , while LVEF was unchanged and LVTEI decreased significantly. Therefore, it was concluded that left ventricular diastolic function improved. Furthermore, since PIIIP decreased significantly, and since a negative correlation was seen between change in PIIIP and change in E , the improvement in left ventricular diastolic function was considered to be via an inhibitory effect on myocardial fibrosis. In addition, mBP and HbA1c decreased significantly, but no correlation was observed between change in mBP and change in E , or between change in HbA1c and change in E . Therefore, we determined that the improvement in left ventricular diastolic function was not associated with a pioglitazone-induced decrease in blood pressure or decrease in blood glucose.
In the OFF group, discontinuation of oral administration of pioglitazone resulted in a significant decrease in E , while LVEF was unchanged and LVTEI increased significantly. Therefore, it was concluded that left ventricular diastolic function deteriorated. PIIIP did not change significantly, but a negative correlation was observed between change in PIIIP and change in E . Accordingly, discontinuation of oral administration of pioglitazone might have resulted in deterioration of left ventricular diastolic function after attenuation of its inhibitory effect on myocardial fibrosis. In addition, since no correlation was observed between change in mBP and change in E , or between change in HbA1c and change in E , we concluded that the improvement in left ventricular diastolic function was not associated with a pioglitazone-induced change in blood pressure or change in blood glucose. An association between the rate of progression of myocardial fibrosis due to aging and diabetes and the rate of onset/cessation of the inhibitory effect of pioglitazone on myocardial fibrosis might have affected PIIIP levels, which showed no significant difference. A significant difference in PIIIP might have been absent due to the small sample size.
Conclusion
Six months of pioglitazone administration suppressed the synthesis of type III collagen, and this was associated with improved left ventricular diastolic function in type 2 diabetic patients. And cessation of pioglitazone weakened the suppression of the synthesis of type III collagen, which in turn seemed to be associated with worse left ventricular diastolic function.
